Founded as Quantitative Radiology Solutions, Quantaras focuses on providing personalized cancer treatment through advanced medical imaging analysis. Their core mission is to enhance cancer treatment decisions by offering precise identification and analysis of anatomical structures and diseased tissues using MRI, CT, and PET/CT images. The flagship product, Quantaras Contour Companion, is an FDA-cleared, cloud-based software that automates the contouring of organs at risk in the head, neck, and thorax, aiding clinicians in optimizing radiation therapy planning.
Notable figures associated with Quantaras include its founders and key investors from the medical technology sector. The company has achieved significant milestones, including FDA clearance for its Contour Companion software, which underscores its reliability and effectiveness. Quantaras' impact is evident in its contribution to improving cancer treatment outcomes by enabling more accurate and personalized radiation therapy, thereby enhancing patient care and optimizing clinical workflows.
